Copenhagen, 2011-11-05 10:21 CET (GLOBE NEWSWIRE) --
ALK's partner in North America, Merck, presents data from two pivotal clinical Phase III studies with its investigational sublingual Ragweed Allergy Immunotherapy Tablet (AIT) at the annual meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Boston, USA.
Both Phase III studies met the combined primary efficacy endpoint of reducing allergy symptoms and use of concomitant symptom relieving medication and the efficacy results were consistent between the two studies. At the meeting in Boston, Merck presents, among other things, data showing that patients treated with the highest dose in the two studies experienced a 24% and 27% reduction (p<0.05), respectively, in the combined primary efficacy endpoint. The registration studies also shows that the treatment was well tolerated, with adverse events (AEs) experienced by subjects receiving the drug similar to previous studies in adults, with no new or unexpected findings. The most commonly reported treatment-related AEs in both studies were as expected, transient local application site reactions in the throat, ear, and mouth (throat irritation (29% and 21%), ear pruritus (16% and 12%) and oral pruritus (19% and 8%)). The studies were conducted by Merck, ALK's strategic partner in North America. A total of approximately 1,350 subjects were included in the studies.
It is estimated that some 60 million people in North America suffer from allergies. Ragweed is a significant North American seasonal, airborne allergen affecting an estimated 50% of American allergy sufferers.
In the clinical development programme to date, two pivotal efficacy and safety studies and two safety studies have been completed for Ragweed AIT.
This announcement does not change ALK’s outlook for the financial year 2011.
ALK-Abelló A/S
Jens Bager
President and CEO
For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143
About Ragweed AIT and the Phase III studies
The investigational Ragweed AIT treatment is designed to work by inducing a protective immune response against ragweed allergy and providing sustained prevention of allergy symptoms, treating both the symptoms and the underlying cause of the disease.
The studies were North American multicenter, randomised, placebo-controlled, double-blind, parallel-group clinical trials evaluating the efficacy and long term safety of the ragweed sublingual tablet versus placebo in the treatment of ragweed-induced rhinoconjunctivitis over a one year period based on the combined (sum of) rhinoconjunctivitis daily symptom score and rhinoconjunctivitis daily medication score. In the studies, approximately 1,350 adults received either placebo or ragweed tablet.
About the partnership with Merck, known as MSD outside the USA and Canada
In January 2007, Schering-Plough (merged with Merck in November 2009) signed an agreement with ALK to develop, register and commercialise a combined portfolio of tablet based allergy immunotherapy against grass, ragweed and house dust mite allergy in North America.
It is estimated that some 60 million people suffer from allergy in North America alone, an estimated 25 million of whom have been diagnosed as suffering from moderate to severe allergy. The majority of these patients suffer from an allergy to grass, ragweed or house dust mites, and in many cases the disease and allergy symptoms are not well-controlled. Thus there is a significant unmet need for better treatment.
At present, up to three million Americans are being treated with a special form of injection based immunotherapy preparations. The treating physicians prepare the named patient products after having received the active allergen ingredients from, for instance, ALK. No registered products for allergy immunotherapy are currently available in North America.
